Patient demographics and baseline characteristics of symptomatic MM patients
| Patient demographics and baseline characteristics . | % of normal PC from all BMPC (N-PC/BMPC) . | P . | |
|---|---|---|---|
| ≤ 5% (n = 514) . | > 5% (n = 80) . | ||
| Male/female* | 283 (55%)/231 (45%) | 48 (60%)/32 (40%) | NS |
| Age, y | 58 (32-70) | 58 (35-70) | NS |
| Subtype of MM* | |||
| IgG | 304 (59%) | 37 (46%) | .06 |
| IgA | 123 (24%) | 17 (22%) | NS |
| Bence-Jones protein | 82 (16%) | 22 (27%) | .04 |
| Nonsecretory | 5 (1%) | 4 (5%) | NS |
| ISS* | |||
| Stage I | 180 (35%) | 38 (48%) | .03 |
| Stage II | 226 (44%) | 30 (37%) | NS |
| Stage III | 108 (21%) | 12 (15%) | NS |
| β2-microglobulin, mg/L† | 3.2 (0.09-41) | 2.5 (0-24) | .009 |
| Hemoglobin, g/L† | 106 (10-167) | 121 (60-168) | < .001 |
| Albumin, g/dL† | 3.6 (0.3-7) | 3.8 (1.8-6.4) | .02 |
| Platelet count, ×109/L† | 207 (6-990) | 241 (58-486) | < .001 |
| M-component, g/dL† | 4 (0-47) | 2 (0-22) | < .001 |
| Immunoparesis, 1 or 2 Ig* | 427 (83%) | 34 (42%) | .003 |
| Plasma cells by morphology, %† | 40% (1-100%) | 17 (1-95) | < .001 |
| Plasma cells by MFC, %† | 13 (0.1-90) | 1.6 (0.05-22) | < .001 |
| Plasma cells in S-phase, %† | 1.4 (0-15) | 2.0 (0-15) | NS |
| CD117+ cases by MFC, n (%)* | 175 (34) | 39 (49) | .04 |
| Patient demographics and baseline characteristics . | % of normal PC from all BMPC (N-PC/BMPC) . | P . | |
|---|---|---|---|
| ≤ 5% (n = 514) . | > 5% (n = 80) . | ||
| Male/female* | 283 (55%)/231 (45%) | 48 (60%)/32 (40%) | NS |
| Age, y | 58 (32-70) | 58 (35-70) | NS |
| Subtype of MM* | |||
| IgG | 304 (59%) | 37 (46%) | .06 |
| IgA | 123 (24%) | 17 (22%) | NS |
| Bence-Jones protein | 82 (16%) | 22 (27%) | .04 |
| Nonsecretory | 5 (1%) | 4 (5%) | NS |
| ISS* | |||
| Stage I | 180 (35%) | 38 (48%) | .03 |
| Stage II | 226 (44%) | 30 (37%) | NS |
| Stage III | 108 (21%) | 12 (15%) | NS |
| β2-microglobulin, mg/L† | 3.2 (0.09-41) | 2.5 (0-24) | .009 |
| Hemoglobin, g/L† | 106 (10-167) | 121 (60-168) | < .001 |
| Albumin, g/dL† | 3.6 (0.3-7) | 3.8 (1.8-6.4) | .02 |
| Platelet count, ×109/L† | 207 (6-990) | 241 (58-486) | < .001 |
| M-component, g/dL† | 4 (0-47) | 2 (0-22) | < .001 |
| Immunoparesis, 1 or 2 Ig* | 427 (83%) | 34 (42%) | .003 |
| Plasma cells by morphology, %† | 40% (1-100%) | 17 (1-95) | < .001 |
| Plasma cells by MFC, %† | 13 (0.1-90) | 1.6 (0.05-22) | < .001 |
| Plasma cells in S-phase, %† | 1.4 (0-15) | 2.0 (0-15) | NS |
| CD117+ cases by MFC, n (%)* | 175 (34) | 39 (49) | .04 |
Patient demographics and baseline characteristics of symptomatic MM patients grouped according to the percentage of N-PC/BMPC.
MM indicates multiple myeloma; N-PC/BMPC, normal plasma cells from all bone marrow plasma cells; PC, plasma cells; BMPC, bone marrow plasma cells; NS, statistically not significant (P > .05); ISS, international staging system; and MFC, multiparameter flow cytometry.
Results expressed as percentage of cases.
Results expressed as median (range).